Despite the seemingly simple definition, EMT is an extremely complex process, activated by pleiotropic intrinsic and extrinsic factors and finely regulated temporally and spatially (10). It involves several molecular re-engineering that instigates polarised epithelial cells, which ordinarily interact with basement membrane through its basal surface to ultimately gain mesenchymal features. Consequently, loss of apical-basal polarity, enhanced motility, invasiveness, immunosuppression, and increased resistance to cell death and therapy result owing to the acquisition of stem cell-like properties (11). Meanwhile, the hallmark of EMT is the inhibition of E-cadherin. Suppression of E-cadherin results in reduced cell adhesion and imposition of migratory mesenchymal cells. This process is not a snap approach. Even though it was previously believed that the transition of tumour cells from pure epithelial to pure mesenchymal state followed a binary-switch model, the emerging knowledge shows that E→M transition is involved with a complex dynamic process through a phenotypic spectrum. Again, the EMT is a highly conserved phenomenon involving corporations among TFs, effector proteins, and signalling molecules that rely on the activity of TFs as effector molecules.

Generally, EMT is characterised by the suppression of epithelial markers particularly involving the intercellular junction protein complex made up of gap junction proteins (such as connexin) adherens junction proteins (particularly, E-cadherin), tight junction proteins (occludin, claudin, and junctional adhesion molecules), cytokeratins, and catenins, as shown in Figure 1 . Primarily, E-cadherin is the most notable among all epithelial markers for its gatekeeping role to avert EMT by acting in concert with the intercellular adhesion system to maintain cellular polarity, differentiation, migration, and signalling in proliferation pathways. Consequently, loss of E-cadherin promotes the transformation of stationary epithelial cells to a migratory mesenchymal phenotype through a cascade process involving several intermediate E/M phenotypes. Apart from mutation, loss of E-cadherin may also be orchestrated by downregulation due to epigenetic or transcriptional silencing (12, 13). All the same, mesenchymal markers such as vimentin, N-cadherin, fibronectins, smooth muscle actin, and matrix metalloproteases (MMP) also become upregulated and function concurrently with the loss of E-cadherin during the EMT program (14) ( Figure 1 ). Altogether, these effector proteins collaborate to induce rearrangement of cellular architecture leading to destabilisation in cellular adhesion, proteolytic degeneration of basement membrane, increased motility (15), and generation of circulating tumour cells (CTCs) ( Figure 1 ).

Even though downregulation of E-cadherin has been shown to induce EMT independently in some cancer models (16, 17), a study carried out by Vafaizadeh and her colleagues (18) suggests that active β-catenin is essential for invasion in culture and experimental metastasis model attributed in part to detachment of adherens junctions during early EMT and subsequent degradation. Deducing in tandem with their structural arrangement, the implication of these findings is that β-catenin acts cooperatively with E-cadherin to initiate EMT ( Figure 2 ), suggesting that β-catenin may be an important therapeutic target in certain types of cancer.

More so, various coordinated events that occur in EMT are controlled by a set of TFs in a cell-specific and context-dependent manner (19, 20). As illustrated in Figure 2 , there is vast evidence that these factors are themselves controlled by various signalling pathways and microenvironment signals such as tumour growth factor-beta (TGF-β), epidermal growth factor (EGF), oestrogen, platelet-derived growth factor (PDGF), WNT, hedgehog (SHH), Notch, and integrins (21–26). In addition to induction of EMT by TFs and signalling molecules, certain types of cellular effectors, such as microRNAs, have also been implicated for their roles in stimulating EMT through TFs. In essence, epithelial-mesenchymal transition TFs (EMT-TFs) perform central roles during the EMT program, which is fundamental to various processes in tissue growth and organ development.

Before now, most experimental models have defined EMT as a binary transition of tumour cells between EMT and MET as mentioned above. However, this oversimplification has caused some confusion, as it fails to explain the real phenomena of the current knowledge, which may not address the limitations of modern clinical settings. Several attempts have been made to elucidate the mechanistic process of EMT through various studies and town hall discussions. Recently, during the 2017 and 2019 meetings of The EMT International Association (TEMTIA), the new concept of “epithelial-to-mesenchymal plasticity” (EMP) was introduced (27), thus broadening the traditional definition of EMT to accommodate the newly discovered features such as the partial activation of EMT, and the existence of a continuous spectrum of hybrid EMT/MET phenotype. Presently, the construction of mathematical models and EMT trajectory by single-cell transcriptomics has enhanced our understanding of the existence of multiple intermediate steps with various degrees of E or M states (28, 29) ( Figure 3 ). This intermediate E/M phase is characterised by various degrees of molecular markers such as E-cadherin, vimentin, β-catenin, etc., depending on the level of EMT-TF expression or inhibition

Remarkably, emerging studies have suggested that the hybrid E/M status can be further divided into several phases based on the combination of different markers they display, as shown in Figure 3 . This proposal was supported by a genetically modified skin squamous cell carcinoma model, showing that neoplastic cells commit to spontaneous EMT and that the hybrid E/M status was divided into early and late hybrid E/M states according to the expression patterns of the surface markers CD106, CD61, and CD51 (30). The emerging concept of plasticity of EMT/MET through transitional states is further discussed extensively later in this report.

The cornerstone of every EMT and its reverse, i.e., mesenchymal-epithelial transition (MET) program, is the transcriptional regulators that control the gene expression required for the cellular transitions. The most widely studied among these factors are zinc-finger proteins (SNAIL), zinc-finger E-box-binding homeobox (ZEB), and Twist family of basic helix-loop-helix (bHLH) transcription factors (TWIST) (31, 32) which are altogether called EMT-TFs ( Table 1 ).

EMT-TFs are gene expression regulators that direct selective gene expression according to the demand of a cell. Their activities are localized in the nucleus, where they have immediate accessibility to the DNA. A common feature of all EMT-TFs is their physiological roles in embryogenesis and organismal development. However, studies have confirmed their aberrant reappearance in cancer cells during tumour development and progression (40, 41). They are activated in the early events of EMT, and they could hence be said to play cardinal roles in development, fibrosis, and tumour aggressiveness. Sometimes, they control the expression of each other and function synergistically at target genes (42).

The conventional feature of all TFs is the direct/indirect inhibition of E-cadherin expression, resulting in the imposition of mesenchymal state and loss of epithelial cell surface biomarkers to gain effective change in phenotype (4). Barring genetic mutations, the overall effect of EMT-TFs on the degradation of E-cadherin to initiate EMT pathway characterizes a structural transformation in the biological properties of epithelial cells. While it is important to understand the mechanisms involved in phenotypic changes from one cellular architecture to another, the roles of individual EMT-inducing TFs cannot be overemphasised as a functional basis for loss of cellular configuration/polarity in epithelial cells, which in turn influences invasion, cell migration, and resistance to anoikis.

All snail protein members encode transcriptional repressors with a similar structural organisation. The C-terminal domain is exceptionally conserved, containing four- to five-type zinc fingers (C2H2) which oversee sequence-specific binding to the E-box element (5′-CAG GTG-3′) of the target genes (43). The N-terminal in humans contains the evolutionarily conserved SNAG domain, which is important for the binding of various transcriptional corepressor complexes to enforce repression of the target genes (44). The central region of Snail is characterised by a serine-rich domain (SRD) and a nuclear export sequence (NES) that regulate protein stability and subcellular localisation of Snail, respectively.

Snail member proteins are the most widely studied modulators of E-cadherin expression, including Snail, Slug, and Smuc. As opposed to Snail and Slug, the involvement of Smuc in the EMT process of human carcinomas is not yet established (45), according to the available data at present. However, as the paradigm of tumour metastasis keeps evolving, it may be worthwhile to investigate the possible involvement of Smuc in different cancer models.

Also, E-cadherin is the hallmark of EMT, and its suppression is mainly attributed to the functions of Snail1 and Snail2 expressions by binding directly to the E-box of the promoter region and downregulate their expressions (8). EMT-TFs do not only inhibit E-cadherin expression but also downregulate the transcription of other genes encoding the epithelial junction proteins such as claudin (46), ZO-1 (47), both of which serve to stabilise the tight junctions. This implies that any biological process that tends to upregulate Snail expression will encourage EMT. In addition, Snail1 has also been shown to enhance the expressions of matrix degradation enzyme matrix metalloproteinases 9 (MMP9) (48), leading to EMT cascade, as a consequence of proteolytic action of MMP that reshapes the extracellular matrix and deconstructs the epithelial membrane (49).

Snail has long been known as an effector molecule for various signalling pathways that direct their functions. For instance, because Snail is a vital regulator of E-cadherin, scientists have asked whether the effects of the Notch on this process could be mediated through the Notch intracellular domain (NICD) via regulation of Snail1. The answer to this is affirmative since Notch has been shown to indirectly promote EMT through regulation of Snail ( Figure 2 ). In further agreement with this, Kar et al. (50) reported that activation of Notch-1 promotes EMT via the repression of E-cadherin by Slug. Similarly, a study carried out by Niessen and his colleagues showed that activation of the Notch in the context of TGF-β stimulation results in synergistic upregulation of Snail in endothelial cells (51). From the above study, it is clearly understood that TGF-β signalling plays a key role in the pathogenesis of tumour metastasis and thus could function as a potential target in controlling tumour progression.

As indicated earlier, TFs regulate the expression of one another. For instance, when E-cadherin expression is suppressed, the expression of Snail proteins (SNAI1/SNAI2) is amplified by an autoactivation loop due to the inhibition of nuclear factor-κB (NF-κB) (52). Therefore, the self-stimulation loop of Snail is engendered by the downregulation of E-cadherin via SNAIL (Snail1/Snail2). This insinuates that Slug is not only a transcriptional repressor but also a transcriptional activator. Intriguingly, Twist1 also binds directly to E-box on the Slug promoter as a transcriptional activator to induce Slug transcription (53). Likewise, Slug is essential for Twist1 to induce EMT. Meanwhile, a knockdown of Slug completely blocks the ability of Twist1 to suppress E-cadherin transcription (54). By implication, Twist1 activity is insufficient to induce cancer cell invasion and distant metastasis in the absence of Slug, making it an attractive therapeutic target.

Apart from EMT modulation, Snail protein members also block the cell cycle, promote cell survival, and inhibit apoptosis, with additional roles in the induction of metastasis and acquisition of cancer stem cell-like characteristics (55, 56). These findings were further supported by separate reports establishing Slug to increase the amount of CD44, a marker of cancer stem cells (CSCs) (57, 58). By implication, the CSC membrane marker could be a potential target for tumour detection, metastatic prevention, selection of drug targets, and other possible intervention strategies.

Another important TF, known as zinc-finger E-box binding homeobox, or ZEB, also modulates the transition of epithelial cells to mesenchymal phenotype. Generally, homeobox genes are conserved in plants, fungi and animals. In humans, the ZEB family proteins are made up of two homologous proteins; ZEB1 (δEFI) and ZEB2 (SIP1) which constitute zinc-finger TFs (59). Structurally, they include two ZnF domains, N-terminal ZnF and C-terminal ZnF. The homeodomain consists of three-alpha helices. In this segment, the helix-loop-helix (or helix-turn-helix (HTH)) motif functions as the E-box-binding site and allows the protein to bind to the E-cadherin promoter region (42), and thus regulates the transcription of the adjacent DNA. Generally, the homeobox codes for a specific sequence that functions as part of evolutionarily conserved signalling pathways, which is particularly active in morphogenesis.

Currently, the roles of the proteins of ZEB have been further implicated in tumorigenesis and metastasis as a resultant disruption of morphogenesis. They function through transcriptional inhibition of the E-cadherin gene (CDH1) by binding the promoter site known as a consensus sequence in addition to corepressor recruitment, histone deacetylase process, and chromatin condensation ultimately initiating EMT (60).

In physiological states, however, the proteins of ZEB mainly occur in the heart, CNS, skeletal muscle, and hematopoietic cells to support organ development. Particularly, ZEB1 is commonly found in the thymus during T-lymphocyte development; whereas, ZEB2 is chiefly found in the spleen during B-lymphocyte development (61), suggesting specific functionality and expression. However, evidence of ZEB1 upregulation has been reported in different cancer types such as pancreatic, lung, liver, colon, and breast cancers (62–66). In the same vein, Yilmaz and Christofori (67) demonstrated that increased expression of ZEB1 decreased the response of cancer cells to therapy. These studies predict that ZEB1 could be an important target in anticancer drug resistance.

By interconnection, Snail1 and Twist1 mutually regulate the expression of ZEB1 (68), while the activated ZEB1, in turn, downregulates multiple genes that enforce epithelial characteristics (69), which is the main event in tumour metastasis. In other words, these proteins could be implicated as markers of poor clinical outcomes in patients with a solid tumour, most especially in the metastatic drive. Akin to the Snail family, various signalling molecules modulate ZEB1 and ZEB2 expression. For instance, TGF-β, Wnt/β-catenin, PI3K/Akt, and Ras/Erk signalling induce ZEB1 (70) ( Figure 2 ), whereas micro-RNAs negatively regulate the expression.

Furthermore, posttranscriptional phosphorylation of ZEB1 also has the propensity to modulate their expression levels, the functional role that was not immediately understood. Although, recent findings have proposed an inhibitory effect on ZEB1 function. For instance, Llorens et al. (71) reported that phosphorylation of ZEB proteins within C-terminal ZnF inhibits the ZEB binding to DNA and its transcriptional activity. This study shows that ZEB1 phosphorylation could perform many functions particularly in crosslinking the TGF-β signalling with many other pathways involving signalling molecules (cytokines and growth factors) within the cellular microenvironment.

In mammals, two bHLH TFs have been identified, Twist1 and Twist2. These two factors share structural similarities and, as such, bind to the same E-box of DNA response elements of the target genes to regulate their expression (72). They are the most characterized indirect transcriptional repressors of the CDH1 promoter, and they play an essential role in embryo formation, wound healing, and tissue fibrosis (73, 74). In adulthood, they are either deficient or expressed at extremely low levels (75), making their molecular underpinning a striking phenomenon for further study, especially in pathogenesis.

Unsurprisingly, scientific studies have shown that Twist proteins are upregulated in carcinogenesis (76, 77) and metastasis (77). Apart from inhibiting the expression of the epithelial marker, Twist1 also increases the expression of mesenchymal markers, including vimentin, N-cadherin, and fibronectin, reducing cellular adhesion and promoting cellular motility (77, 78). In addition, Twist proteins generally promote cancer stem cell phenotype (79), which explains its association with poor prognosis.

By regulation, posttranslational modification of Twist proteins can impact their functions both positively and negatively; for instance, phosphorylation of Twist1 by MAP enhances its stability, promoting invasiveness and EMT in breast cancer cells (80). Contrastingly, IKKβ-mediated phosphorylation promotes the degradation of Twist proteins (81), providing an insight into possible regulation of EMT, which could further prevent tumour cell motility, invasion, and accordingly, cancer metastasis. Understanding the accumulation of Twist protein as a precursor for cancer metastasis, the “brake system” of this molecular purview renders IKKβ a potential novel target for future therapeutic design in the fight against cancer metastasis.

Apart from the TFs that have been studied extensively, previous studies have indicated other nonconventional TFs in the EMT process. For instance, goosecoid (GSC) represses E-cadherin expression indirectly (82) and has been found in various metastatic breast cancer (83). Also, Krüppel-like factor 8 (KLF8) enhances EMT induction through direct suppression of E-cadherin by regulating its promoter (84), resulting in improved motility and altered cell morphology, which has been implicated in breast, ovarian, and gastric cancer cell lines (84–87).

Additionally, another less-reported TF known as paired-related homeobox 1 (PRRX1) also plays important role in tumorigenesis and promotes tumour invasion. PRRX1 with two isoforms—PRRX1a and PRRX1b—exerts distinct functions in EMT. A report from recent studies shows crucial roles of PRRX1 via isoform switching during MET, tumour invasion, and metastasis of pancreatic malignancy (88). The study further suggests that PRRX1b isoform stimulates cellular de-differentiation, EMT initiation, and tumour invasiveness while the PRRX1a isoform could induce cell differentiation and the MET (88). Encoded in humans by the PRRX1 gene, the PRRX1 protein functions primarily act as a transcription coactivator, which enhances the DNA-binding activity of serum response factor that induces many genes by growth and differentiation factors.

Similarly, another superfamily of transcriptional regulators named forkhead box (FOX) proteins is emerging as important regulatory players in various gene expressions associated with cell growth, proliferation, and differentiation. Akin to the common TFs, some FOX proteins are also important drivers in embryonic development and biological shift in cellular phenotypes, which may be linked with maintenance of epithelial polarity via E-cadherin function.

In particular, a report in the literature shows that forkhead box C2 (FOXC2) induces EMT by indirect suppression of E-cadherin (89). In effect, FOXC2 plays a crucial role in embryogenesis and angiogenesis, among other physiological processes (90, 91). More importantly, FOXC2 contributes to the metastatic process via EMT activation in many cancer growths and developments involving cancers of the breast, prostate, and ovary (92–94). Furthermore, using human tumour cell lines, the investigation also reveals that suppression of FOXC2 by short hairpin RNA (shRNA) in an aggressive metastatic breast cancer model could halt the metastatic tendency (92) suggesting that FOCX2 is not only a promising molecular marker for cancer detection but also a potential therapeutic target. Currently, very few TFs remain “druggable.” Worse still, the existence of many TFs outside the nuclear receptor family poses difficulty in targeting those recognisable TFs with small molecule therapeutics, partly due to paucity of data. Therefore, it might be worthwhile to try out targeting the less-exploitable TFs such as GSC, KLF8, PRRX1, FOCX2, GRHL2, and other poorly investigated similar molecules considering their potential regulatory roles within various signalling pathways.

In contrast to the EMT-inducing transcription factors, molecular mechanisms inhibiting EMT are inadequately characterised as of now. Meanwhile, as scientific efforts are intensifying to decipher the batteries of factors that regulate EMT, there seems to be some cheering news as emerging studies continue to provide evidence of possible spontaneous inhibition of EMT through some special transcription factors. These factors could be referred to as proepithelial factors or anti-EMT factors. Some of these factors include OVO-like transcriptional repressor (OVOL1, OVOL2), grainyhead-like transcription factor 2 (GRHL2), CCAAT-enhancer-binding protein alpha (C/EBPα), oestrogen receptor (ER), and p53. Their major role is to counterbalance the EMT-TFs thereby safeguarding the continued residence of cells in an epithelial state (93).

OVOL protein family, including OVOL1 and OVOL2, are the vertebrate homologs of Drosophila OVO and have been regarded as critical regulators of cellular transformation both in physiological and diseased states. Even though they are also members of the zinc-finger protein family, they are known as the anti-EMT transcription factors that promote the epithelial status. They are functionally important in the embryogenesis of vertebrates and for the maintenance of an epithelial state and terminal differentiation during tissue homeostasis (94). Mechanistically, OVOL1/2 can suppress EMT by direct inhibition of EMT-TFs, such as ZEB1, ZEB2, and TWIST. In addition, it promotes the reverse of EMT, that is, MET (95, 96), thereby inducing the expression of the cell-cell adhesion molecule called E-cadherin.

However, the extent of the reversal remains a conundrum and requires further investigations since the generation of hybrid EMT will amount to more aggressive malignancy and may portray OVOL proteins as spurious anti-EMT factors. Although the existence of varying hybrid EMT intermediates (as depicted in Figure 3 ) could explain different levels of invasiveness, plasticity, and migratory potential, a deeper understanding of how OVOL1 and OVOL2 promote epithelial differentiation and inhibit EMT in the context of different metastatic models, maybe rewarding to reliably label OVOL factors as useful therapeutic candidates. A report that seems to partially address this concern from Wu and colleagues revealed that OVOL2 thwarts TGF-β signalling and blocks EMT during breast tumour metastasis by repressing SMAD4 expression and interfering with SMAD4 and SMAD2/3 complex formation (97). More recently, Xu et al. proposed that OVOL1 coordinates the suppression of proliferation, invasion, and migration in oral squamous cell carcinoma cells by inhibiting ZEB1 expression via direct binding to its promoter (98). This further endorses the OVOL2/ZEB1 feedback loop as the controller of the epithelial-mesenchymal plasticity across several carcinomas.

Recently, mathematical modelling of the feedback circuit between ZEB1 and OVOL2 has revealed that in addition to epithelial and mesenchymal states, cells can acquire one or more hybrid epithelial/mesenchymal states (99). In other words, this has been considered the most plastic and aggressive state (99), hence reinforcing the concern about how beneficial OVOL could be as a novel therapeutic signature for overcoming tumour progression. While OVOL1 and OVOL2 have been described as gatekeepers that prevent mesenchymal trans-differentiation and maintain epithelial identity, their regulation is poorly understood.

OVOL1 or OVOL2 knockdown has been shown to significantly increase the mRNA levels of both vimentin and ZEB1. This led to an extensive functional study of OVOL proteins by Maho et al. (100). The study employed two precancerous conditions, actinic keratosis (AK) and cutaneous squamous cell carcinoma (cSCC) and showed that OVOL1 and OVOL2 were upregulated in AK and significantly downregulated in cSCC. While ZEB1 and vimentin were upregulated in cSCC, most AK cells were negative or faintly express the proteins, suggesting that downregulation of OVOL1/2 and upregulation of ZEB1 and vimentin may be associated with the progression of AK to cSCC. Taken together, this study provides abundant evidence to support the pro-MET features of OVOL factors and the importance of the OVOL2/ZEB1 axis in the maintenance of epithelial status. Thus, the OVOL1/2-ZEB1 axis can form an important axis of regulation of EMT in cancer progression.

The grainyhead-like (GRHL) family of transcription factors consist of three members, GRHL1, GRHL2, and GRHL3, which were first discovered in Drosophila melanogaster (101). Out of these, GRHL2 has been widely associated with neoplastic diseases. The roles of GRHL2 in tumour pathogenesis seem to be complex and controversial, varying with cancer type (102). Recently, the signalling pathways between EMT and GRHL2 have attracted considerable attention from researchers. In different cancer models, upregulation of GRHL2 expression has been directly correlated with lower EMT scores; whereas, cancers with mesenchymal features have reduced GRHL2 expression. In cultured human colorectal cancer cells, GRHL2 upregulation promotes epithelial states by reversing the epithelial-like shape from a spindle-like shape and increases E-cadherin, β-catenin, and ZO-1, while vimentin is significantly downregulated (103).

A recent study discovered that TGF-β-induced EMT is inhibited by GRHL2, preventing invasion and migration of gastric cancer. In turn, inhibition of TGF-β signalling pathways increased GRHL2 expression (104). Similarly, GRHL2 significantly inhibits TGF-β-induced, Twist-induced, and spontaneous EMT in breast cancer (105). Further mechanistic studies reveal that GRHL2 is directly inhibited by ZEB1, which in itself, a direct target for repression by GRHL2 (106), suggesting that GRHL2 and ZEB1 form a double-negative regulatory feedback loop in breast cancer cells.

The p53 tumour suppressor, also known as the “genome guardian,” plays a dominant role in maintaining genome stability and protects the DNA against mutagenesis (107). p53 plays diverse tissue regulatory roles through several mechanisms. It can be regarded as a transcription factor that acts in response to various stress cues, causing cell cycle arrest, cell ageing, and apoptosis. In addition, p53 plays a vital role in controlling the metabolism and antioxidant status of cells (108). Beyond this, p53 has been associated with anti-EMT roles, by restricting the plasticity of epithelial cells during EMT.

Essentially, p53 indirectly promotes M→E by attenuating EMT-TFs (109) via the upregulation of EMT-suppressing miRNAs. Thus, p53 has the potential to avert EMT and the associated stem cell-like phenotype across multiple cancers. Categorically, p53 induces the expression of miR-200c, miR-183, and miR-34, which target ZEB, SNAIL, and TWIST families of transcription factors (110). In other words, apart from maintaining genome integrity, a functioning p53 gene would also be crucial for the maintenance of epithelial integrity.

The transcription factor CCAAT enhancer-binding protein α (C/EBPa) is a widely expressed basic leucine zipper transcription factor that plays a critical role in cellular differentiation (111). It plays a pivotal role in the regulation of the cell cycle and the expression of several lineage-specific genes (112). Recent findings provided persuasive proof that C/EBPα is an important transcription factor required to sustain epithelial architecture of human mammary cells, preventing epithelial-to-mesenchymal transition and thereby acting as a repressor of breast cancer progression in vivo (113). C/EBPα factor can activate and represses several target genes, and its roles in the maintenance of epithelial traits have been attributed to its direct transcriptional activation of epithelial markers, such as CDH1 (E-cadherin) and suppression of EMT-TFs such as ZEB1 (114). This is consistent with previous data on hepatocellular carcinoma, where C/EBPα is shown to be a critical negative regulator of TGF-β-induced EMT, promoting inhibition of N-cadherin and maintenance of E-cadherin expression (114).

Since CEBPA mRNA levels were instantly suppressed upon TGF-β treatment, Ana et al. (113) proposed that SMAD3 may be responsible for the repression of CEBPA transcription. This sounds logical since SMAD3 was found to occupy the CEBPA locus upon TGF-β treatment. Depletion of SMAD3, owing to impaired TGF-β-mediated repression of CEBPA, supports a downstream regulatory role for SMAD3 as a transcriptional repressor of C/EBPα expression during TGF-β-induced EMT.

The oestrogen receptor, especially the alpha class, (ERα) plays a cardinal role in blocking the EMT process ( Figure 2 ). For example, metastasis-associated protein 3 (MTA3), directly activated by ERα, downregulates Snail expression (115). Also, ERα directly inhibits Slug transcription by forming a corepressor complex consisting of ligand-activated ERα, histone deacetylase 1 (HDAC1), and nuclear receptor corepressor (NCoR) that binds to the oestrogen-response elements at the Slug promoter sequence (115, 116).

Therefore, the absence of ER or MTA3 results in abnormal expression of Snail and Slug diminishing the ER activity to promote metastasis, chemoresistance, and recurrence after treatment (117, 118). These findings justify why ER is regarded as a marker of poor clinical outcomes and an important therapeutic target in breast cancer (119). Thus, through many significant molecular mediations in connection with tumorigenesis, EMT, and metastatic cascade, it might be possible to develop a novel drug targeting the associated ER-signalling components in women breast cancer intervention.

As stated earlier, EMT-TFs are regulated by various intracellular signalling networks ( Figure 2 ). It starts with the extracellular molecules binding to its particular membrane receptor to initiate intracellular signal transduction. The transforming growth factor, wnt, oestrogen, fibroblast growth factor (FGF), PDGF, and the Jagged family bind to TGF-β receptor (TGFβR), Frizzled, oestrogen receptor (ER), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGF-R), and Notch, respectively (120–122). The ligand-bound receptors transduce intracellular signals via the pathways, such as MAPK, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt), nuclear factor-κB (NF-kB), β-catenin, or the Smad signalling, which regulate the expression and stability of EMT-TFs (121) ( Figure 2 ).

Previous findings have shown that these networks of signalling interface at various strata and numerous feedback activation and inhibition mechanisms have been illustrated in different EMT contexts, with the possibility of showing overlapping and context-specific results (123, 124). This highlights the importance of delineating the induction of these pathways in various subpopulations of cancer cells following EMT activation to understand possible therapeutic targets in various human carcinomas.

Notably, the dominant roles of TGF-β in EMT must be acknowledged. It is a well-elucidated molecule that induces EMT in various cellular contexts, cancer inclusive. The functions of TGF-β in cancer vary from one biological setting to another, deciphering its dual relevance in tumour pathogenesis, which has been called the “TGF-β paradox” (125). In the early tumour stage, TGF-β supports apoptosis and inhibits the proliferation of tumour cells. Conversely, it plays a tumour-promoting role in the later stage by stimulating EMT, genomic instability, angiogenesis, cell motility, and metastasis.

Following successful binding to its receptor (TGF-βR), it activates several signalling cascades, including Ras-MAPK and SMAD-dependent signalling. Activation of the RAS-MAPK induces expression of Snail1 and Snail2, ultimately leading to the repression of E-cadherin (103). TGF-β can also initiate gene expression through activation of the Notch, and Wnt pathways, which then lead to activation of Snail1 and Snail2, expression of mesenchymal markers, and EMT induction via degradation of intracellular catenins (33) ( Figure 2 ).

In addition to ligand-receptor interactions, environmental signals such as oxygen reduction in the cellular environment can as well directly activate TGF-β through hypoxia-inducible factor 1 alpha (HIF-1α) (126) which in turn leads to gene transcription. More so, HIF-1α can initiate epigenetic modulation of EMT by targeting the transcription of histone deacetylase 3 genes (HDAC3), cooperating with Snail and ZEB expressions to suppress epithelial expression (127), with the imposition of mesenchymal characteristics.

Furthermore, there is compelling evidence in recent years to support the significant role of Notch in the EMT process (128–130). This is not surprising because the pathway is the nexus of an adaptable signalling network that controls various cellular mechanisms in different biological contexts—determined by the tissue microenvironment (131, 132). Notch signalling explores two discrete channels to synergistically regulate the expression of EMT-TFs (133). Firstly, direct activation of TFs by mobilising the Notch intracellular domain (NICD) to their promoter and secondly, by potentiating HIF-1α recruitment to the lysyl oxidase (LOX) promoter to aid the hypoxia-induced upregulation of LOX, which stabilises Snail and safeguarding it from protein degradation (134). Importantly, the signals generated from this pathway usually stimulate transcriptional repressors (Snail1/2, ZEB1/2, and TWIST1/2) to promote and regulate EMT.

Fortunately, studies have proven that inhibition of Notch signalling by the small interfering RNA (siRNA) system promotes reversal of the EMT phenotype, resulting in the MET by inhibiting ZEB1, Slug, Snail, and NF-κB (135). These data present molecular evidence connecting Notch signalling with neoplastic drug resistance validated by EMT phenotype. This suggests that inactivation of Notch signalling with a novel targeted therapeutic approach could be conceived to subdue chemoresistance toward preventing tumour progression, for which present traditional therapeutic strategies are grossly dissatisfying.

Interestingly, Snail could also regulate the Notch expression. Kuphal et al. (136), for example, found downregulation of Notch-4 by antisense Snail cDNA transfection of melanoma cells, and the results are convincing in support of the complex crosstalk between Notch and Snail during the acquisition of EMT. These findings indicate the complex contribution of different TGF-β to EMT in carcinoma cells and, therefore, represent an intimidating obstacle in formulating a therapeutic model to control the EMT in human tumours.

MicroRNAs (miRNAs) are a small class of noncoding RNAs that modulate gene expression by RNA silencing, translational suppression, and mRNA degradation (137). They are involved in many biological processes involving cell differentiation, proliferation, cell death, and tumour invasion (138). Another report shows that miR-200 and miR-205 members can mediate EMT suppression by direct inhibition of ZEB1 and ZEB2, thus enhancing the tumour sensitivity to therapeutic interventions (139). In addition, the expression of miR-204/miR-29b demonstrates the blockage of metastasis and cancer invasion considerably in gastric cancer cell lines via Snail1-induced EMT suppression (140). Unsurprisingly, however, the low expression level of the miR-200 family in breast cancer enhances ZEB1/ZEB2 transcriptions, inducing TGF-β/BMP signalling to sustain EMT (141). Also, Kim et al. (110) reported that p53 negatively modulates EMT in cancer of the liver upregulating the miR-200 and miR-192 expression by targeting inhibition of ZEB1/ZEB2 expression.

Activation of p53 targets many microRNAs—miR-200c, miR-183, and miR-34—by inducing their expressions. This process, in turn, downregulates some EMT-TFs such as ZEB and Snail. Consequently, the chain reaction in the signalling cascade directly results in EMT suppression and thus MET activation. In essence, induction of TGF-β, mutations, or epigenetic silencing which may cause loss of p53 could ultimately stimulate the EMT process (142).

Inhibition of EMT in the early steps of invasion and metastasis, which perhaps promises to be the most cost-effective approach, has been the talking point in the scientific community of late. As earlier highlighted, the interplay and crosstalk between TFs and other signalling molecules orchestrate and mandate adjacent epithelial tumour cells to undergo EMT, leading to tumour progression, invasiveness, metastasis, and therapeutic resistance in some cancers. These TFs act as downstream effector molecules for the cascade. Thus, breaking the crosstalk between TFs and these pathways is a reasonable option for arresting tumour cells from metastasising and limiting drug resistance. Although these factors were for a long time considered “undruggable” targets (156), a deeper understanding of their specific expression pattern, degradation, mode of binding, protein/protein interaction, as well as interaction with other signalling pathways has changed this narrative. Additionally, it has also opened new possibilities to affect transcription factors as therapeutic targets for cancer treatment. Furthering the exploits through another perspective, signalling crosstalk, understanding that molecular modulators in one pathway are enzymatic (transcriptional) targets of another that sometimes compete with the original modulators, the undruggable bottleneck could end in a breakthrough.

Among the promising opportunities to indirectly or directly target a transcription factor are inhibition (or activation) at the expression level; inhibition through physical degradation; inhibition (or activation) at the protein interaction level; and inhibition (or activation) through the binding of a ligand-based molecule in an activation/inhibition pocket and inhibition (or activation) at the protein/DNA binding level. For example, when Snail was blocked in a high-grade serous ovarian cancer cell line (HGSOC), cancer stemness was reversed by decreasing CSC markers (CD117 and CD133) (157).

Similarly, Zhang et al. demonstrated that Snail knockout in MCF-7 breast cancer cells initially resistant to 5-FU resulted in reversal of EMT declined cell invasion and improved sensitivity to 5-FU (158). Consequent to the various studies about Snail and the correlation with chemoresistance and cancer stem cells, targeting Snail is a fascinating approach to overcome EMT and cancer resistance, which suggests that Snail inhibitors could prevent tumour recurrence. Inactivation of Twist1 expression by linolenic acid (ALA) treatment markedly reduces cell migration (159). Recently, a small molecule, CYD19, was identified to bind strongly with Snail and inhibited its interaction with CREB-binding protein (160). The altered interaction leads to impairment of CBP/p300-mediated Snail acetylation and rapid degeneration of Snail via the proteasomal pathway.

Furthermore, studies have shown that inhibition of γ-secretase would prevent the cleavage of the Notch receptor, thereby blocking Notch signal transduction (161, 162). In this way, the expression of Snail and ZEB proteins are kept in check so that E-cadherin retains its function to maintain epithelial characteristics. Thus, γ-secretase inhibitors can be clinically tried for treating human malignancies. Disappointingly, however, despite the repeated promising preclinical results on the control of tumour progression, gamma-secretase inhibitors (GSIs) have failed to demonstrate clinical benefit in most solid tumours. The poor clinical performance to date calls for important questions that are yet to be answered. Perhaps, refinement of tumour Notch expression profiles and further mechanistic understanding of GSIs will necessarily assist appropriate patient selection.

Also, more innovative approaches may include the rational design of combinatorial strategies to maximise the potential of these agents by sensitising tumours to traditional chemotherapeutics while also compromising tumour ability to engage treatment resistance programs. However, it is worthy of note here that caution should be applied while designing GSIs to eliminate undesired toxicity associated with the γ-secretase inhibitors, as they are involved in a wide array of cellular functions.

Even though, as earlier suggested, interfering EMT transition might be a step forward in the prevention of cancer metastasis, intratumour heterogeneity poses several hurdles against successful therapeutic design. As a result, understanding the E/M cellular transitional plasticity along a phenotypic spectrum would be central to more precise diagnoses and increasing the susceptibility of cancer cells to therapeutic manipulations, thus overcoming the current spate of drug resistance.

Several studies dispute the role of EMT in cancer metastasis as a result of their failure to detect EMT in the process, thus suggesting a striking controversy in cancer biology. Worse still, the use of individual EMT biomarkers from the bulk-tissue approach has repeatedly failed to answer the question of where gene upregulation or downregulation arises among the heterogeneous components involving malignant cells, the surrounding stroma and immune infiltrate. Thus, a method that can offer a direct and unbiased characterisation of individual cell’s (gene) expression to unveil intratumoural heterogeneity would therefore provide clarity over the age-old questions, and perhaps, paves way for targeted therapy. Therefore, the roles of novel technologies such as single-cell analysis would be invaluable to improve understanding of the underlying molecular mechanisms of tumour heterogeneity and investigation of diverse intermediates of E/M cells during EMT.

Intriguingly, it is now widely established that trans-differentiation of E/M cells and their intermediates are the main cause of intratumour heterogeneity and that the disseminated cancer cells need to revert towards a more epithelial phenotype to increase the sensitivity of neoplastic cells to therapeutic interventions. To therapeutically target EMT and indeed, the metastable pEMT state, it is essential to extensively evaluate the duplex modulations that shuttle cells towards or away from E and M states. Presumably, the bidirectional inhibitions that targets both EMT and MET might be an effective strategy to destabilise the M or hybrid states, while avoiding an escape route to a different resistant state. With this in mind, we anticipate the next few decades will represent a major acceleration in our knowledge of EMT and its entire spectrum of states. This is expected to aid in the stratification of patients into low- and high-risk cohorts while opening up entirely new avenues in the treatment of epithelial tumours.

Given the considerable heterogeneity of the tumour ecosystem, it is essential to analyse the molecular and genetic characteristics of each cell (163), rather than employing the bulk-tissue approaches. Fortunately, the emergence of single-cell sequencing technology has come to the rescue, enabling cells undergoing a transition to be inspected as single cell instead of collective cell populations. To simply put, with single-cell analysis, it would be possible to obtain complete genomic information of the entire cells concerning EMT gene regulatory circuits along the EMT continuum and compare them with the corresponding primary tumours. Through this, several clinically relevant genomic alterations could be discovered to provide valuable information for promising diagnostic and therapeutic opportunities. Specifically, single-cell RNA sequencing (ScRNA-seq), which provides high-throughput and high-resolution transcriptomic analyses of individual cells has been used to eliminate much of the background noise within a mixed population of cells. With a temporal profile, it will allow investigators to probe the genomic, transcriptomic, epigenomic, or other multiomics dynamics of heterogeneous cell populations because it can measure the distribution of genes and gene products (mRNA and proteins) from individual cells. With scRNA, one can encapsulate cell trajectories and developmental processes such as EMT by applying a scRNA-seq time course to assemble a cell trajectory map (164). Generating an EMT time-course to capture transient cell states at single-cell resolution informs the investigator with information on how this dynamic process occurs over time, thereby providing an elegant resource that is not available in any other known way. ScRNA-seq method is a recently developed technology with a promising prospect at providing a transcriptomic analysis of individual cells to address the inherent complexity of EMT milieu in tumour metastasis and its tumour environment. Despite the promising prospect of this novel method, some technical barriers have been identified.

Firstly, both cellular integrity and viability largely determines the success or otherwise of the subsequent single-cell analyses. It means that distinct cells need to be isolated from each other promptly while avoiding mechanical damage to the cells during the single-cell isolation process. However, this cellular segregation may impair cell integrity and enzymatic treatment using trypsin, collagenase, and/or papain to isolate single cells from tissues. In other words, it may affect cell viability or alter the transcriptional products. Hence, this necessitates the need for improve approaches to enable the efficient “gentle” extraction and capture of living cells and avoid the potential damage to single cells caused by enzymatic treatment.

Again, researchers have used scRNA-seq to analyse the association between therapeutic response and specific infiltrated immune cells in the tumour environment (165). At this point, another gap to be filled by ScRNA-seq is to enable rationale strategies that can identify drug-resistant cell populations associated with poor prognosis to achieve long-term treatment efficacy and combinatorial therapeutics that can aid in cotargeting multiple activated pathways.